Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
EBITDA Over TimeStrong
Percentile Rank93
3Y CAGR+3.4%
5Y CAGR+7.2%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
+3.4%/yr
vs +17.8%/yr prior
5Y CAGR
+7.2%/yr
Recent deceleration
Acceleration
-14.4pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $5.82B | +9.4% |
| 2024 | $5.32B | +13.3% |
| 2023 | $4.69B | -10.8% |
| 2022 | $5.26B | -45.6% |
| 2021 | $9.67B | +135.7% |
| 2020 | $4.10B | +53.7% |
| 2019 | $2.67B | -2.2% |
| 2018 | $2.73B | +21.4% |
| 2017 | $2.25B | +56.0% |
| 2016 | $1.44B | - |